Description
1. Triple Mechanism of Action
Unlike semaglutide (which targets one receptor) or tirzepatide (which targets two), retatrutide targets three key metabolic receptors:
- GLP-1: Reduces appetite and slows stomach emptying.
- GIP: Enhances insulin secretion and nutrient management.
- Glucagon Receptor (GCGR): Increases energy expenditure (calorie burning) and stimulates the breakdown of stored fat.
2. Weight Loss and Clinical Results (2026 Update)
Phase 3 trials reported in early 2026, such as TRANSCEND-T2D-1, have shown significant results:
- Total Weight Loss: In clinical trials, participants on the highest 12mg weekly dose lost an average of 24.2% to 28.7% of their body weight over 48 to 80 weeks.
- Comparison: This is notably higher than the weight loss typically seen with semaglutide (~15%) or tirzepatide (~21%).
- Metabolic Benefits: It has demonstrated substantial reductions in HbA1c (blood sugar), liver fat (steatosis), and waist circumference.
3. Critical Safety and Performance Concerns
Because of the added glucagon component, retatrutide carries unique risks not as prevalent in other GLP-1s:
- Heart Rate Increases: It is associated with dose-dependent increases in resting heart rate (averaging 5–10 beats per minute), peaking around week 24 before declining.
- Cardiac Arrhythmias: Clinical trials noted a higher incidence of mild-to-moderate cardiac arrhythmias (2–11%) compared to placebo.
- Lean Mass Loss: Like all rapid weight-loss medications, there is a risk of significant loss of lean muscle tissue alongside fat if not paired with high-protein intake and resistance training.
- Standard Side Effects: Nausea, vomiting, diarrhea, and constipation remain the most common reasons for treatment discontinuation.
Reviews
There are no reviews yet.